Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MGMT | P16455 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437095 | 1.00 | NAAA (0.58) | NAAATSHRABCG2CYP1A2CYP2D6 | |
| SCHEMBL13671097 | 1.00 | NAAA (0.58) | NAAATSHRABCG2CYP1A2CYP2D6 | |
| SCHEMBL13671096 | 1.00 | NAAA (0.58) | NAAATSHRABCG2CYP1A2CYP2D6 | |
| SCHEMBL13671102 | 1.00 | NAAA (0.58) | NAAATSHRABCG2CYP1A2CYP2D6 | |
| SCHEMBL17414391 | 0.96 | NAAA (0.53) | NAAATSHRABCG2CYP1A2CYP2D6 | |
| SCHEMBL17162030 | 0.95 | NAAA (0.54) | NAAATSHRABCG2CYP1A2CYP2D6 | |
| SCHEMBL21070168 | 0.87 | NAAA (0.49) | NAAATSHRABCG2TDP1L3MBTL1 | |
| SCHEMBL30458266 | 0.86 | NAAA (0.42) | NAAAABCG2MGMT | |
| SCHEMBL14448284 | 0.84 | ABCG2 (0.47) | NAAATSHRABCG2 | |
| SCHEMBL16682544 | 0.84 | NAAA (0.41) | NAAAABCG2MGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-8252778-B2 | Highly fluorinated oils and surfactants and methods of making and using same | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090264397-A1 | HIGHLY FLUORINATED OILS AND SURFACTANTS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | NAAA 4811/4885TSHR 4739/4885ABCG2 1278/4885 |
| US-20090264397-A1 | HIGHLY FLUORINATED OILS AND SURFACTANTS AND METHODS OF MAKING AND USING SAME | FLOT1, ABCB4, SGMS1 | NAAA 741/4885TSHR 3279/4885ABCG2 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.